REGENXBIO Inc. RGNX
7.40
0.16
2.21%
as of 25 Sep
- Market cap
- $487.8M
- P/E
- 0.0×
Follow RGNX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (137.63%) | (196.43%) | (107.00%) | (76.88%) |
+8 more TTM periods Free account |
|
| (40.60%) | (69.65%) | (42.19%) | (34.07%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(77.95%) | (133.47%) | (72.33%) | (56.50%) | |
Average Days of Receivables |
223.32 | 41.72 | 56.49 | 57.35 | |
Free Cash Flow per Share |
(4.73) | (4.51) | (2.45) | (2.06) | |
Free Cash Flow |
(249.67) | (236.40) | (126.38) | (106.28) | |
Capital Expenditures |
(2.99) | (2.62) | (2.41) | (2.98) | |
Piotroski F-Score |
2.00 | 1.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(138.97%) | (136.26%) | (37.25%) | (23.71%) | |
Accounts Receivable Turnover |
2.75 | 6.22 | 7.28 | 6.59 | |
Accounts Payable Turnover |
1.28 | 1.39 | 0.92 | 0.99 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
238.73 | 277.08 | 384.06 | 392.84 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
131.32% | 264.80% | 133.95% | 135.80% | |
Selling, General and Administrative Expense of Revenue |
49.03% | 95.45% | 48.62% | 49.92% | |
Share Based Compensation of Revenue |
20.08% | 39.45% | 20.28% | 22.15% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.26 | 0.81 | 0.64 | 0.58 | |
Depreciation/Fixed assets |
0.17 | 0.15 | 0.15 | 0.15 | |
Capex/Depreciation |
(0.18) | (0.17) | (0.15) | (0.19) | |
Revenue per Share |
3.30 | 1.68 | 3.30 | 3.12 | |
Operating CF per Share |
(4.67) | (4.46) | (2.40) | (2.00) | |
Capex per Share |
(0.06) | (0.05) | (0.05) | (0.06) | |
Capex to Sales |
0.02 | 0.03 | 0.01 | 0.02 | |
Net Profit Margin |
(112.58%) | (330.23%) | (113.75%) | (110.29%) |
Columns are period end dates